Stanford School of Medicine, Palo Alto, CA, USA.
MAbs. 2010 Mar-Apr;2(2):148-56. doi: 10.4161/mabs.2.2.11159.
Currently, a wide variety of both polyclonal and monoclonal antibodies are being routinely utilized to prevent and treat solid organ rejection. More commonly, these agents are also administered in order to delay introduction of calcineurin inhibitors, especially in patients with already compromised renal function. While these antibody therapies dramatically reduced the incidence of acute rejection episodes and improved both short and long-term graft survival, they are also associated with an increased incidence of opportunistic infections and neoplastic complications. Therefore, effective patient management must necessarily balance these risks against the potential benefits of the therapy.
目前，广泛使用的多克隆和单克隆抗体被常规用于预防和治疗实体器官排斥。更常见的是，这些药物也被用于延迟钙调磷酸酶抑制剂的引入，特别是在已经存在肾功能受损的患者中。尽管这些抗体治疗显著降低了急性排斥反应的发生率，并改善了短期和长期移植物的存活率，但它们也与机会性感染和肿瘤并发症的发生率增加有关。因此，有效的患者管理必须在治疗的潜在益处与这些风险之间进行权衡。
